文献速递神经肿瘤

激酶组药物筛选发现多靶点酪氨酸激酶抑制剂协同作用及ERBB2信号通路为MYC/TYR亚组非典型畸胎样横纹肌样瘤的治疗脆弱性

A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.
PubMed 文献 · Neuro Oncol · 2024-01-01

本研究对465种激酶抑制剂在非典型畸胎样横纹肌样瘤(ATRT)亚组特异性细胞系中进行筛选,发现ATRT细胞系对PI3K、MAPK通路抑制剂及CDK、AURKA/B、PLK1抑制剂广泛敏感。在MYC/TYR亚组中,PDGFRB抑制剂达沙替尼与雷帕霉素或曲美替尼协同抑制细胞生长,且ERBB2信号通路抑制剂(包括阿法替尼)在体外和体内特异性抑制MYC/TYR ATRT细胞生长。作者认为PDGFR和ERBB2靶向TKI联合PI3K/MAPK通路抑制剂是MYC/TYR亚组ATRT的重要新治疗策略。

要点

  • ATRT细胞系对PI3K、MAPK、CDK、AURKA/B和PLK1抑制剂广泛敏感。
  • MYC/TYR ATRT细胞中达沙替尼与雷帕霉素或曲美替尼协同抑制生长。
  • 阿法替尼在体外和体内特异性抑制MYC/TYR ATRT细胞生长。

核心结论

  • 作者认为PDGFR和ERBB2靶向TKI联合PI3K和MAPK通路抑制剂是MYC/TYR亚组ATRT的重要新治疗策略。

研究设计与样本

  • 研究检测了465种激酶抑制剂对一组ATRT亚组特异性细胞系的效果。
  • 采用多组学分析探究ATRT亚组中激酶抑制剂疗效的分子机制。

主要发现

  • ATRT细胞系对PI3K和MAPK信号通路抑制剂以及CDK、AURKA/B激酶和polo样激酶1抑制剂广泛敏感。
  • 在MYC/TYR ATRT细胞中鉴定出主要靶向受体酪氨酸激酶(包括PDGFR和EGFR/ERBB2)的两类多激酶抑制剂。
  • PDGFRB抑制剂达沙替尼与广谱PI3K和MAPK通路抑制剂(包括雷帕霉素和曲美替尼)联合时协同影响MYC/TYR ATRT细胞生长。
  • MYC/TYR ATRT细胞对多种ERBB2信号抑制剂 distinctly 敏感。
  • 原发性MYC/TYR ATRT的转录、H3K27Ac ChIPSeq、ATACSeq和HiChIP分析揭示ERBB2表达,其与差异甲基化和通过DNA环化激活的独特增强子元件相关。

临床怎么用

  • 作者认为联合PDGFR和ERBB2靶向TKI与PI3K和MAPK通路抑制剂是MYC/TYR亚组ATRT的重要新治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atypical teratoid rhabdoid tumor (ATRT) is a rare, devastating, and largely incurable pediatric brain tumor. Although recent studies have uncovered 3 molecular subgroups of ATRTs with distinct disease patterns, and signaling features, the therapeutic profiles of ATRT subgroups remain incompletely elucidated. METHODS: We examined the effect of 465 kinase inhibitors on a panel of ATRT subgroup-specific cell lines. We then applied multiomics analyses to investigate the underlying molecular mechanism of kinase inhibitor efficacy in ATRT subgroups. RESULTS: We observed that ATRT cell lines are broadly sensitive to inhibitors of the PI3K and MAPK signaling pathways, as well as CDKs, AURKA/B kinases, and polo-like kinase 1. We identified 2 classes of multikinase inhibitors predominantly targeting receptor tyrosine kinases including PDGFR and EGFR/ERBB2 in MYC/TYR ATRT cells. The PDGFRB inhibitor, Dasatinib, synergistically affected MYC/TYR ATRT cell growth when combined with broad-acting PI3K and MAPK pathway inhibitors, including Rapamycin and Trametinib. We observed that MYC/TYR ATRT cells were also distinctly sensitive to various inhibitors of ERBB2 signaling. Transcriptional, H3K27Ac ChIPSeq, ATACSeq, and HiChIP analyses of primary MYC/TYR ATRTs revealed ERBB2 expression, which correlated with differential methylation and activation of a distinct enhancer element by DNA looping. Significantly, we show the brain penetrant EGFR/ERBB2 inhibitor, Afatinib, specifically inhibited in vitro and in vivo growth of MYC/TYR ATRT cells. CONCLUSIONS: Taken together, our studies suggest combined treatments with PDGFR and ERBB2-directed TKIs with inhibitors of the PI3K and MAPK pathways as an important new therapeutic strategy for the MYC/TYR subgroup of ATRTs.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Golbourn B, Ho B, Bondoc A, et al. A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors. Neuro Oncol. 2024. PMID: 38981018. doi:10.1093/neuonc/noae120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。